Diversity, Equity and Inclusion:
As members of PhRMA, we believe improving human life means celebrating human diversity
Commitment to DE&I
We are committed to a fair, equitable and non-discriminatory workplace where there are meaningful platforms for dialogue and progress. This starts from the top – our managers are expected to act as role models for our values every day. We are committed to creating a gender-balanced and inclusive workplace, and to see change, we have to start with our people.
Takeda’s Center for Health Equity and Patient Affairs
We launched our R&D Center for Health Equity and Patient Affairs (HEPA). HEPA operates as a center of excellence, positioning Takeda as a leader in health equity and patient centricity to create a more inclusive ecosystem and strengthen trust and reputation with patients and other key external stakeholders around the world. It works to ensure that DE&I considerations inform our planning for clinical trials and other research and development activities.
Talent Acquisition, Development & Retention
Takeda has and will continue to strengthen our talent acquisition processes with an enhanced focus on diversity, equity and inclusion. There are a number of initiatives underway:
• Implementation of Bias reducing tool (in final stages with technology vendors)
• Roll out of DE&I and Behavioral Based interview training
• Implementation enterprise-wide Candidate Relationship Management (CRM) tool connected with Applicant Tracking System (ATS) to create inclusive talent communities
Environmental Sustainability:
As members of PhRMA, we believe a healthy environment is essential for improving human life
Carbon Neutrality
Takeda achieved carbon neutrality across its value chain in 2020 for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets.
Our Commitment to Environmental Sustainability for a Brighter Future
By 2025, we commit to reducing GHG emissions in our operations by 40% from FY2016 levels. We will cut Scope 3 emissions by 15% based on FY2018 levels.
By 2024, we will help 67% of our suppliers to establish their own science-based emissions targets.
We are committed to working to achieve net-zero GHG emissions in our operations before 2035. By 2040, we are committed to reaching net-zero for our entire value chain, including currently estimated scope 3 GHG emissions.
Sustainability by Design
Our Sustainability by Design program aims to minimize our environmental footprint by incorporating sustainability principles during every stage of product development. The activities involve R&D, Drug Products & Processing and Packaging and Devices. They are designed to minimize the environmental impact of all future products throughout their life cycle.
Access & Affordability:
As members of PhRMA, we believe that living our mission of improving human life relies on broad access to medicines
Access to Medicines
At Takeda, we’re committed to broadening sustainable access to our innovative medicines in low- and middle-income countries and in countries with evolving health care systems.
Global Corporate Social Responsibility Program
Takeda’s Global CSR Program supports activities in developing and emerging countries that prevent disease, train health workers, strengthen supply chains, and improve access to quality diagnosis and treatment. We make robust, long-term funding commitments, recognizing that there are no quick fixes and that sustainable impact takes time. We actively partner with world-class organizations and NGOs with proven track records of addressing global health problems in innovative, enduring ways.
As of September 2022, contributions from the Global CSR program total JPY 19.7 billion (approximately 140.7 USD) across 24 programs in 79 countries since the its launch in 2016.